NO328890B1 - Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse - Google Patents

Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse Download PDF

Info

Publication number
NO328890B1
NO328890B1 NO20041180A NO20041180A NO328890B1 NO 328890 B1 NO328890 B1 NO 328890B1 NO 20041180 A NO20041180 A NO 20041180A NO 20041180 A NO20041180 A NO 20041180A NO 328890 B1 NO328890 B1 NO 328890B1
Authority
NO
Norway
Prior art keywords
dimethyl
propyl
carbonitrile
pyrrolo
pyrimidine
Prior art date
Application number
NO20041180A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041180L (no
Inventor
Martin Missbach
Naoki Teno
Kenji Hayakawa
Genji Iwasaki
Claudia Betschart
Osamu Irie
Junichi Sakaki
Rene Lattmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20041180L publication Critical patent/NO20041180L/no
Publication of NO328890B1 publication Critical patent/NO328890B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20041180A 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse NO328890B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (2)

Publication Number Publication Date
NO20041180L NO20041180L (no) 2004-03-19
NO328890B1 true NO328890B1 (no) 2010-06-07

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041180A NO328890B1 (no) 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse

Country Status (29)

Country Link
US (2) US7452886B2 (da)
EP (1) EP1423391B8 (da)
JP (1) JP4629334B2 (da)
KR (1) KR100695845B1 (da)
CN (1) CN100372849C (da)
AR (1) AR036374A1 (da)
AT (1) ATE326469T1 (da)
AU (1) AU2002333760B2 (da)
BR (1) BR0212226A (da)
CA (1) CA2458684C (da)
CY (1) CY1105573T1 (da)
DE (1) DE60211530T2 (da)
DK (1) DK1423391T3 (da)
EC (1) ECSP044998A (da)
ES (1) ES2262888T3 (da)
GB (1) GB0121033D0 (da)
HU (1) HUP0401301A3 (da)
IL (3) IL160367A0 (da)
MX (1) MXPA04001935A (da)
MY (1) MY157368A (da)
NO (1) NO328890B1 (da)
NZ (1) NZ531343A (da)
PE (1) PE20030418A1 (da)
PL (1) PL368280A1 (da)
PT (1) PT1423391E (da)
RU (1) RU2331644C2 (da)
TW (1) TWI297690B (da)
WO (1) WO2003020721A1 (da)
ZA (1) ZA200401042B (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
BRPI0409868A (pt) * 2003-04-28 2006-05-16 Novartis Ag composição farmacêutica que compreende um inibidor da catepsina s e um opióide
US6987194B2 (en) * 2003-04-30 2006-01-17 Fmc Corporation Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
TW200533664A (en) 2004-02-18 2005-10-16 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
US7427682B2 (en) 2004-05-03 2008-09-23 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP1957494A2 (en) * 2005-12-05 2008-08-20 Incyte Corporation Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008032191A2 (en) 2006-09-13 2008-03-20 Astrazeneca Ab Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
PE20090875A1 (es) 2007-10-19 2009-08-08 Astrazeneca Ab Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2644965T3 (es) * 2012-04-17 2017-12-01 Astellas Pharma Inc. Compuesto heterocíclico aromático bicíclico nitrogenado
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
DK3055429T3 (da) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
CN118284609A (zh) * 2021-12-01 2024-07-02 St制药株式会社 用于制备三唑并嘧啶酮衍生物的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE609808A (da) * 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
DK0970084T3 (da) * 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
AU4710699A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Bicyclic sPLA2 inhibitors
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
AU2001247589A1 (en) * 2000-03-20 2001-10-03 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
NZ522217A (en) 2000-04-28 2004-04-30 Tanabe Seiyaku Co Cyclic compounds

Also Published As

Publication number Publication date
ES2262888T3 (es) 2006-12-01
JP2005502683A (ja) 2005-01-27
CN100372849C (zh) 2008-03-05
WO2003020721A1 (en) 2003-03-13
ZA200401042B (en) 2004-10-25
PL368280A1 (en) 2005-03-21
JP4629334B2 (ja) 2011-02-09
AR036374A1 (es) 2004-09-01
AU2002333760B2 (en) 2007-01-04
IL160367A0 (en) 2004-07-25
MXPA04001935A (es) 2004-06-15
CN1549817A (zh) 2004-11-24
EP1423391B1 (en) 2006-05-17
RU2004109815A (ru) 2005-10-20
CA2458684C (en) 2009-04-07
PT1423391E (pt) 2006-09-29
US7452886B2 (en) 2008-11-18
ECSP044998A (es) 2004-04-28
TWI297690B (en) 2008-06-11
DE60211530D1 (de) 2006-06-22
PE20030418A1 (es) 2003-06-12
KR20040029123A (ko) 2004-04-03
KR100695845B1 (ko) 2007-03-20
CA2458684A1 (en) 2003-03-13
EP1423391B8 (en) 2007-12-12
GB0121033D0 (en) 2001-10-24
DE60211530T2 (de) 2006-12-21
NO20041180L (no) 2004-03-19
HUP0401301A3 (en) 2008-03-28
IL198643A (en) 2010-12-30
ATE326469T1 (de) 2006-06-15
CY1105573T1 (el) 2010-07-28
RU2331644C2 (ru) 2008-08-20
US20050054851A1 (en) 2005-03-10
EP1423391A1 (en) 2004-06-02
DK1423391T3 (da) 2006-09-25
NZ531343A (en) 2006-01-27
BR0212226A (pt) 2004-08-17
HK1072254A1 (zh) 2005-08-19
US20090054467A1 (en) 2009-02-26
IL160367A (en) 2009-12-24
HUP0401301A2 (hu) 2004-10-28
MY157368A (en) 2016-06-15

Similar Documents

Publication Publication Date Title
NO328890B1 (no) Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse
AU2002333760A1 (en) Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
US20250129085A1 (en) Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
AU2022221581B2 (en) Imidazole-containing inhibitors of ALK2 kinase
US10738056B2 (en) Pyrazolopyrimidinone compounds and uses thereof
JP4499667B2 (ja) 2−シアノピロロピリミジンおよびその薬学的使用
US7279473B2 (en) Pyrazolopyridazine derivatives
CA2283211A1 (en) 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives
SK5402003A3 (en) Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
MXPA06015223A (es) Furanopirimidinas.
US6821971B2 (en) Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
US7608603B2 (en) Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors
US20050261248A1 (en) New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives
KR20180082432A (ko) 비시클릭 화합물 및 suv39h2 를 저해하기 위한 이의 용도
CA2585557C (en) Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
AU2003218280B8 (en) 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6849627B2 (en) 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
HK1072254B (en) Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees